Primary liver cancer
Conditions
Interventions
Treatment group: bushenjianpijiedu granules in combination with entecavir tenofovir disoproxil or tenanol alafenol Fovir antiviral therapy
Control group:The control group was given placebo in combination with entecavir tenofovir disoproxil or tenanol alafenol Fovir antiviral therapy
Sponsors
Anhui Hospital Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Meet the above diagnostic criteria for precancerous lesions of hepatitis B cirrhosis; (2) Patients with liver regenerative nodules =3mm detected by B-ultrasound, CT or MRI; (3) Age 18~65 years old, gender is not limited; (4) Sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with liver cirrhosis caused by other hepatotropic virus infections; (2) Those with presence or suspicion of primary hepatocellular carcinoma mass detected by B-ultrasound, CT or MRI; (3) Patients with Child-Pugh grade C greater than 12 points, and upper gastrointestinal bleeding and hepatic bleeding in the past 6 months Patients with encephalopathy, hepatorenal syndrome; (4) Patients with serious primary diseases of heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract; or spiritual patients; (5) persons with disabilities in the sense of the law; (6) Pregnant or lactating women; (7) Patients with allergies or allergies to multiple drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function;HBV markers;Four items of liver fibrosis;B ultrasound;Alpha-fetoprotein;HBVDNA;TCM Syndrome Integral Scale; | — |
Countries
China
Contacts
Public ContactZhou Zhenhua
Anhui Hospital Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed